Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0000899243-22-028185
Filing Date
2022-08-09
Accepted
2022-08-09 21:18:32
Documents
2
Period of Report
2022-08-08

Document Format Files

Seq Description Document Type Size
1 FORM 4 SUBMISSION doc4.html 4  
1 FORM 4 SUBMISSION doc4.xml 4 7965
2 EX-24 DOCUMENT attachment1.htm EX-24 4425
  Complete submission text file 0000899243-22-028185.txt   13910
Mailing Address 222 JACOBS STREET SUITE 200 CAMBRIDGE MA 02141
Business Address 222 JACOBS STREET SUITE 200 CAMBRIDGE MA 02141 844-304-2048
Cerevel Therapeutics Holdings, Inc. (Issuer) CIK: 0001805387 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations

Mailing Address C/O AEON BIOPHARMA, INC. 4040 MACARTHUR BLVD., SUITE 260 NEWPORT BEACH CA 92660
Business Address
Akamine Scott (Reporting) CIK: 0001816720 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-39311 | Film No.: 221150177